## CMB International Securities | Equity Research | Company Update

# Meituan (3690 HK)

## Moving into 2Q22E recovery

Meituan delivered largely in-line 3Q21, in which topline beat 1% (+38% YoY) on solid food delivery and in-store & travel, while margin is in-line with our estimate. Looking ahead, mgmt prioritized quality growth with improving efficiency to tackle epidemic and macro headwinds. We are conservative on its 4Q21 & 1Q22E outlook, forecasting food delivery/ In-store, hotel and travel/ new initiatives +19%/+22%/+57% YoY in 4Q21E. Stock price might see near-term volatility for tough 4Q21E and soft sector sentiment. In the long run, we keep confident on its organic growth, and expect gradual rebound from 2Q22E. We trimmed its topline by 1-8% in FY21-23E to reflect ST headwinds, with new TP at HK\$332.

- **3Q21 largely in line.** 3Q21 rev +38% YoY, 1%/1% above consensus/our estimate. Adj. net loss reached RMB5.5bn, better than our estimate of RMB5.6bn, but missed consensus on higher loss of new initiatives. By segment, rev of food delivery/ In-store, hotel and travel/ new initiatives +28%/+33%/+67% YoY (vs. our estimate of +26%/+31%/+70% YoY).
- Conservative outlook in 4Q21 & 1Q22E on epidemic and macro. 3Q21E food delivery GTV/orders +29.5%/25% YoY (above our estimates of +28%/+25% YoY), with take rate at 13.4% in 3Q21 (in-line). Adj. OPM was 3.3%, slightly above our estimate at 3.0%. Looking ahead, we expect food delivery to see near-term deceleration until 2Q22E, due to soft season in 4Q, epidemic resurgence and challenging macro. 4Q21E food delivery rev +19% YoY, with OPM at 5.5%, by our estimate. 3Q21 in-store, hotel and travel rev +33% YoY, while OPM beat our expectation (44%, vs. our estimate of 40%). Epidemic might still pose one-off impact on in-store biz in 4Q21E (forecasting rev +22% YoY, with OPM at 40%), but long-term trend remains intact.
- Shifting to quality growth, with improving efficiency. 3Q21 new initiatives +67% YoY, with net loss at RMB10.9bn (vs. our estimate of RMB10.5bn). We estimate 4Q12E new biz rev +57% YoY, while net loss at RMB11.5bn in 4Q21E (Meituan Select <RMB7.0bn, with improving UE). Daily orders of tier 1 players reached 50mn in 11.11 (based on channel check), suggesting sequential growth in 3Q21, despite slower expansion pace.</p>
- Maintain BUY. To reflect tough outlook in next few quarters on epidemic and macro, we trimmed its topline by 1-8% in FY21-23E, and slightly cut our SOTP-based TP to HK\$332. Maintain BUY.

## Earnings Summary

Lanningo Oannary					
(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	97,529	114,795	178,388	232,676	297,613
YoY growth (%)	50	18	55	30	28
Net income (RMB mn)	4,657	3,121	(18,180)	(4,811)	13,698
EPS (RMB)	0.79	0.52	(2.94)	(0.76)	2.10
YoY growth (%)	NA	(34)	NA	NA	NA
Consensus (RMB)	NA	NA	(2.6)	(0.10)	2.81
P/E (x)	275	416	NA	NA	103
P/S (x)	13.6	11.6	7.4	5.7	4.5
Yield (%)	0.0	0.0	0.0	0.0	0.0
ROE (%)	3.7	5.0	(39.9)	(22.5)	9.9
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates



## **BUY (Maintain)**

Target Price	HK\$332.2
(Previous TP	HK\$383.0)
Up/Downside	+25.7%
Current Price	HK\$264.6

### **China Internet Sector**

Sophie Huang (852) 3900 0889 sophiehuang@cmbi.com.hk

### Stock Data

Mkt Cap (HK\$ mn)	1,628,180
Avg 3 mths t/o (HK\$ mn)	6,028.09
52w High/Low (HK\$)	460.0/ 183.2
Total Issued Shares (mn)	5,457
Source: Bloomberg	

#### Shareholding Structure

Tencent	19.5%
Sequoia Capital	6.5%
Baillie Gifford	5.0%
Source: Bloomberg	

#### Share Performance

	Absolute	Relative
1-mth	-5.3%	-0.8%
3-mth	41.7%	41.1%
6-mth	-0.4%	13.6%
Source: Bloomberg	r	

#### 12-mth Price Performance



Source: Bloomberg

#### Auditor: PwC

#### **Related Reports**

- 1. China Internet: Embracing a new normal of regulation 8 Nov 2021
- Looking beyond 3Q21E epidemic impact – 27 Oct 2021
- Regulation & epidemic impact manageable - 31 Aug 2021



## Figure 1: CMBIS estimates vs consensus

		CMBIS			Consensus		Diff (%)			
RMB mn, Dec-YE	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	178,388	232,676	297,613	182,319	251,154	327,628	-2.2%	-7.4%	-9.2%	
Gross Profit	41,769	78,497	106,396	44,544	71,934	101,214	-6.2%	9.1%	5.1%	
Operating Profit	(26,236)	(13,666)	6,905	(21,082)	(6,410)	13,197	NA	NA	-47.7%	
Adj. net profit	(18,180)	(4,811)	13,698	(15,621)	(626)	17,324	NA	NA	-20.9%	
EPS (RMB)	(2.94)	(0.76)	2.10	(2.58)	(0.10)	2.81	NA	NA	-25.3%	
Gross Margin	23.4%	33.7%	35.7%	23.7%	28.3%	30.6%	-0.3ppts	+5.5ppts	+5.2ppts	
Operating Margin	-14.7%	-5.9%	2.3%	-10.5%	-1.0%	5.3%	-4.2ppts	-4.8ppts	-2.9ppts	
Adj. Net Margin	-10.2%	-2.1%	4.6%	-8.2%	0.8%	6.3%	-2.0ppts	-2.9ppts	-1.7ppts	

Source: Company data, Bloomberg, CMBIS estimates

## Figure 2: Earnings revision

		New			Old		Diff (%)			
RMB mn, Dec-YE	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	178,388	232,676	297,613	180,891	253,279	324,840	-1.4%	-8.1%	-8.4%	
Gross Profit	41,769	78,497	106,396	46,138	91,076	119,299	-9.5%	-13.8%	-10.8%	
Operating Profit	(26,236)	(13,666)	6,905	(20,559)	(6,934)	13,022	NA	NA	-47.0%	
Adj. net profit	(18,180)	(4,811)	13,698	(15,465)	(1,105)	17,078	NA	NA	-19.8%	
Adj. EPS (RMB)	(2.94)	(0.76)	2.10	(2.50)	(0.17)	2.61	NA	NA	-19.7%	
Gross Margin	23.4%	33.7%	35.7%	25.5%	36.0%	36.7%	-2.1ppts	-2.3ppts	-1.0ppts	
Operating Margin	-14.7%	-5.9%	2.3%	-11.4%	-2.7%	4.0%	-3.3ppts	-3.2ppts	-1.7ppts	
Adj. net margin	-10.2%	-2.1%	4.6%	-8.5%	-0.4%	5.3%	-1.7ppts	-1.7ppts	-0.7ppts	

Source: CMBIS estimates

## Figure 3: Meituan's 3Q21 review

RMB mn	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	QoQ	YoY	Consensus	Diff %	CMBI	Diff 9
Revenue	19,174	22,703	27,494	28,158	16,754	24,722	35,401	37,918	37,016	43,759	48,829	12%	38%	48,573	1%	48,487	19
Operating profit	(1,304)	1,113	1,447	1,424	(1,716)	2,175	6,724	(2,853)	(4,767)	(3,252)	(10,103)	NA	NA	(7,301)	NA	(7,488)	N/
Net profit	(1,432)	877	1,333	1,463	(1,579)	2,210	6,321	(2,244)	(4,846)	(3,356)	(9,994)	NA	NA	(7,041)	NA	(6,835)	N/
Adj. net profit	(1,039)	1,494	1,942	2,270	(216)	2,718	2,055	(1,437)	(3,892)	(2,217)	(5,527)	NA	NA	(5,244)	NA	(5,613)	N/
Margin (%)																	
Gross margin	31.0%	34.7%	30.6%	24.9%	31.0%	34.7%	30.6%	24.9%	19.5%	28.6%	22.1%			23.8%		21.2%	
Operating margin	-6.8%	4.9%	5.3%	5.1%	-10.2%	8.8%	19.0%	-7.5%	-12.9%	-7.4%	-20.7%			-15.0%		-15.4%	
Adj. net margin	-5.4%	6.6%	7.1%	8.1%	-1.3%	11.0%	5.8%	-3.8%	-10.5%	-5.1%	-11.3%			-10.8%		-11.6%	
Growth (%)																	
Revenue (YoY)	70.1%	50.6%	44.1%	42.2%	-12.6%	8.9%	28.8%	34.7%	120.9%	77.0%	37.9%			37.2%		37.0%	
Revenue (QoQ)	-3.2%	18.4%	21.1%	2.4%	-40.5%	47.6%	43.2%	7.1%	-2.4%	18.2%	11.6%			11.0%		10.8%	
Operating profit	NA	NA	NA	NA	NA	95.5%	364.6%	NA	NA	NA	NA			NA		NA	
Adj. net profit	NA	NA	NA	NA	NA	82.0%	5.8%	NA	NA	NA	NA			NA		NA	

Source: Company data, Bloomberg, CMBIS estimates

## Figure 4: 3Q21 Revenue breakdown

	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	QoQ	YoY
Revenue (RMB mn)	19,174	22,703	27,494	28,158	16,754	24,722	35,401	37,918	37,016	43,759	48,829	11.6%	37.9%
Food Delivery	10,706	12,845	15,577	15,716	9,490	14,544	20,693	21,538	20,575	23,125	26,485	14.5%	28.0%
In-Store, Hotel, Travel	4,492	5,245	6,181	6,357	3,095	4,544	6,478	7,135	6,584	8,602	8,621	0.2%	33.1%
New Initiatives & Others	3,976	4,613	5,736	6,086	4,168	5,634	8,230	9,244	9,856	12,032	13,723	14.1%	66.7%

Source: Company data, CMBIS estimates

## Figure 5: SOTP Valuation

Business (US\$ bn)	'23E Rev	OP Margin	'23E EBIT	Methodology	Multiple	Value
Food Delivery	23.7	8%	1.9	EV/EBIT	38.0x	72.2
In-Store and Travel	6.0	40.0%	2.4	EV/EBIT	28.0x	67.0
Hotel	2.2	40.0%	0.9	EV/EBIT	28.0x	24.3
New initiatives	14.8	-19.4%	(2.9)	EV/Sales	6.5x	96.4
Enterprise Value						259.9
(+) Net Cash						17.9
Equity Value						277.8
Diluted Shares Outstanding (mn)						6,201.0
FY23 Val. Per share(HK\$)						351.0
Discounted back to FY22E (HK\$)						313.4
Average 2022 & 2023 valuation (HK\$)						332.2



## **Financial Summary**

Income statement						Cash flow summa	ary
YE 31 Dec (RMB mn) Revenue Food delivery	<b>FY19A</b> 97,529 54,843	<b>FY20A</b> 114,795 66,265	<b>FY21E</b> 178,388 95,725	<b>FY22E</b> 232,676 121,078	<b>FY23E</b> 297,613 151,198	YE 31 Dec (RMB mn) Net income D&A	<b>FY19</b> 2,23 4,84
In-store, hotel & travel	22,275	21,252	32,510	41,706	51,911	Change in WC	(3,697
New initiatives COGS	20,410 (65,208)	27,277 (80,744)	50,153 (136,618)	69,892 (154,179)	94,504 (191,217)	Others Operating CF	2,18 5,57
Gross profit S&M	32,320 (18,602)	34,050 (20,883)	41,769 (41,029)	78,497 (55,842)	106,396 (62,499)	Capex Associates	(2,210 (8,710
Admin.Exp.	(3,559)	(5,594)	(7,136)	(11,634)	(8,928)	Others	74
R&D Others	(7,309) 475	(10,893) 8,117	(14,806) (5,035)	(18,614) (6,073)	(20,833) (7,231)	Investing CF	(10,174
Operating profit	3,326	4,798	(26,236)	(13,666)	6,905	Equity raised Change of Debts	1,74
Financial Cost	(25)	(156)	(91)	10	(143)	Others	(635
Fair value change	-	-	-	-	-	Financing CF	1,11
Others Pre-tax Income	107 3,408	264 4,906	309 (26,018)	309 (13,346)	309 7,071	<b>Net change in cash</b> Cash (beg of yr)	(3,486 17,04
Income Tax Net profit	(526) 2,236	270 4,708	2,360 (23,865)	2,033 (11,521)	(1,030) 5,834	FX Cash (end of yr)	(173 13,39
Adj. net profit	4,657	3,305	(18,180)	(4,811)	13,698		

Cash now summa	ary				
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Net income	2,236	4,708	(23,865)	(11,521)	5,834
D&A	4,846	4,466	2,558	2,836	3,175
Change in WC	(3,697)	(1,044)	5,973	4,370	8,231
Others	2,189	345	4,460	5,526	6,715
Operating CF	5,574	8,475	(10,875)	1,211	23,955
Capex	(2,210)	(4,305)	(5,708)	(7,073)	(8,595)
Associates	(8,710)	(4,334)	(0)	(0)	(0)
Others	746	(12,593)	4,064	5,036	6,120
Investing CF	(10,174)	(21,232)	(1,644)	(2,037)	(2,475)
Equity raised	-	-	-	-	-
Change of Debts	1,749	4,333	-	-	-
Others	(635)	13,085	-	-	-
Financing CF	1,114	17,418	-	-	-
Net change in cash	(3,486)	4,661	(12,519)	(827)	21,480
Cash (beg of yr)	17,044	13,396	17,094	4,575	3,748
FX	(173)	(964)	-	-	-
Cash (end of yr)	13,396	17,094	4,575	3,748	25,228

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21E	FY22E	FY23E
Non-current assets	49,878	78,269	57,114	56,500	55,989	Sales mix (%)					
Fixed asset	5,376	13,917	-	-	-	Food delivery	56.2	57.7	53.7	52.0	50.8
Financial assets at fair value	7,166	10,863	10,863	10,863	10,863	In-store, hotel & travel	22.8	18.5	18.2	17.9	17.4
Intangible assets	32,700	31,676	30,805	30,007	29,307	New initiatives	20.9	23.8	28.1	30.0	31.8
Others	4,636	21,812	15,446	15,631	15,819	Total	100.0	100.0	100.0	100.0	100.0
Current assets	82,135	88,306	68,452	68,598	91,582	Growth rate (%)					
Cash	13,396	17,094	4,575	3,748	25,228	Revenue	49.5	17.7	55.4	30.4	27.9
Restricted cash	8,760	12,776	8,760	8,760	8,760	Gross profit	114.0	5.4	22.7	87.9	35.5
Account receivable	677	1,031	612	679	781	EBIT	NA	35.9	NA	NA	NA
Others	59,302	57,406	54,505	55,411	56,812	Net profit	NA	(29.0)	NA	NA	NA
Current liabilities	36,593	51,148	43,061	48,559	58,466	P&L ratios (%)					
Trade payable	6,766	11,967	11,043	15,124	21,279	Operating margin	3.4	4.2	(14.7)	(5.9)	2.3
Payable to merchants	7,495	9,415	8,102	8,983	10,341	Pre-tax margin	3.5	4.3	(14.6)	(5.7)	2.4
Advances from users	3,856	4,308	3,071	3,404	3,919	Net margin	4.8	2.9	(10.2)	(2.1)	4.6
Deferred revenues	4,567	5,053	3,802	4,463	5,137	Effective tax rate	(0.5)	0.2	1.3	0.9	(0.3)
Others	13,908	20,405	17,044	16,586	17,790						
						Returns (%)					
Non-current liabilities	3,366	17,793	17,281	17,310	17,326	ROE	3.7	5.0	(39.9)	(22.5)	9.9
Borrowings	467	1,957	1,957	1,957	1,957	ROA	3.7	2.2	(12.4)	(3.8)	10.0
Others	-	-	-	-	-						
Minority interest	2,899	15,835	15,324	15,353	15,369	Per share					
						EPS (RMB)	0.79	0.52	(2.94)	(0.76)	2.10
Total Equity	(58)	(59)	(61)	(64)	(67)	DPS (RMB)	0.00	0.00	0.00	0.00	0.00
Shareholders' equity	92,054	97,634	78,229	72,234	84,783	BVPS (RMB)	15.54	16.26	10.56	9.32	10.98

Source: Company data, CMBIS estimates



## **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.